Log In
Print
BCIQ
Print
Print this Print this
 

vigabatrin (CPP-109)

  Manage Alerts
Collapse Summary General Information
Company Catalyst Pharmaceutical Partners Inc.
DescriptionIrreversible inhibitor of GABA transaminase
Molecular Target GABA transaminase
Mechanism of ActionGABA transaminase inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationTourette's syndrome
Indication DetailsTreat Tourette's disorder
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today